

Calcilytic NPSP795 increases plasma calcium and PTH in an autosomal dominant hypocalcemia type-1 mouse model

Hannan, Fadil; Gorvin, Caroline M; Babinsky, Valerie N; Olesen, Mie; Stewart, Michelle; Wells, Sara; Cox, Roger; Nemeth, Edward; Thakker, Rajesh

License:
Creative Commons: Attribution (CC BY)

Document Version
Peer reviewed version

Citation for published version (Harvard):
Hannan, F, Gorvin, CM, Babinsky, VN, Olesen, M, Stewart, M, Wells, S, Cox, R, Nemeth, E & Thakker, R 2020, 'Calcilytic NPSP795 increases plasma calcium and PTH in an autosomal dominant hypocalcemia type-1 mouse model', *JBMR Plus*.

[Link to publication on Research at Birmingham portal](#)

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.



Calcilytic NPSP795 increases plasma calcium and PTH in an autosomal dominant hypocalcemia type-1 mouse model

Fadil M. Hannan DPhil¹, Caroline M. Gorvin DPhil¹, Valerie N. Babinsky DPhil¹, Mie K. Olesen MSc¹, Michelle Stewart PhD², Sara Wells PhD², Roger D. Cox PhD², Edward F. Nemeth PhD³, Rajesh V. Thakker FRS¹

¹Academic Endocrine Unit, Radcliffe Department of Medicine, Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), University of Oxford, UK. ²MRC Mammalian Genetics Unit and Mary Lyon Centre, MRC Harwell Institute, Harwell Science and Innovation Campus, UK. ³MetisMedica, Toronto, Canada.

Address correspondence to: Rajesh V. Thakker at the Academic Endocrine Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), Oxford, OX3 7LJ, UK. Tel no: 01865 857501. Fax no: 01865 875502. Email: rajesh.thakker@ndm.ox.ac.uk

Running title: NPSP795 increases calcium in ADH1

Footnotes:

Current addresses for Dr Caroline M. Gorvin: Institute of Metabolism and Systems Research and Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham, Birmingham, UK

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/jbm4.10402

Accepted Article

Current address for Dr Fadil M. Hannan: Nuffield Department of Women's and Reproductive Health, University of Oxford, Oxford, UK

Accepted Article

Disclosure: F.M.H. and R.V.T. have received grant funding from NPS/Shire Pharmaceuticals and GlaxoSmithKline for studies involving the use of calcilytic compounds. R.V.T. has also received grants from Novartis Pharma AG and the Marshall Smith Syndrome Foundation for unrelated studies.

Data accessibility: All data will be made available in a public repository such as Figshare after publication of this manuscript.

Abstract

Calcilytics are calcium-sensing receptor (CaSR) antagonists that reduce the sensitivity of the CaSR to extracellular calcium. Calcilytics have the potential to treat autosomal dominant hypocalcemia type-1 (ADH1), which is caused by germline gain-of-function CaSR mutations, and leads to symptomatic hypocalcemia, inappropriately low PTH concentrations and hypercalciuria. To-date, only one calcilytic compound, NPSP795, has been evaluated in ADH1 patients, and doses of up to 30 mg per patient were shown to increase PTH concentrations but did not significantly alter ionized blood calcium concentrations. The aim of this study was to further investigate NPSP795 for the treatment of ADH1 by undertaking *in vitro* and *in vivo* studies involving *Nuf* mice, which have hypocalcemia in association with a gain-of-function CaSR mutation, Leu723Gln. Treatment of HEK293 cells stably expressing the mutant *Nuf* (Gln723) CaSR with 20 nM NPSP795 decreased extracellular Ca^{2+} -mediated intracellular calcium and phosphorylated ERK responses. An *in vivo* dose-ranging study was undertaken by administering a *s.c.* bolus of NPSP795 at doses ranging from 0-30 mg/kg to heterozygous (*Casr^{+/Nuf}*) and to homozygous (*Casr^{Nuf/Nuf}*) mice, and measuring plasma PTH responses at 30 min post-dose. NPSP795 significantly increased plasma PTH concentrations in a dose-dependent manner with the 30mg/kg dose causing a maximal (≥ 10 -fold) rise in PTH. To determine whether NPSP795 can rectify the hypocalcemia of *Casr^{+/Nuf}* and *Casr^{Nuf/Nuf}* mice, a sub-maximal dose (25 mg/kg) was administered, and plasma adjusted-calcium concentrations measured over a 6 hour period. NPSP795 significantly increased plasma adjusted-calcium in *Casr^{+/Nuf}* mice from 1.87 ± 0.03 mmol/L to 2.16 ± 0.06 mmol/L, and in *Casr^{Nuf/Nuf}* mice from

1.70±0.03 mmol/L to 1.89±0.05 mmol/L. Our findings demonstrate that NPSP795 elicits dose-dependent increases in PTH and ameliorates the hypocalcemia in an ADH1 mouse model. Thus, calcilytics such as NPSP795 represent a potential targeted therapy for ADH1.

Abbreviated abstract: Autosomal dominant hypocalcemia type 1 (ADH1) is caused by gain-of-function calcium-sensing receptor (CaSR) mutations, and leads to low PTH concentrations and symptomatic hypocalcemia. This study has demonstrated that NPSP795, a CaSR antagonist, elicits dose-dependent increases in PTH and ameliorates the hypocalcemia in an ADH1 mouse model. Thus, NPSP795 represents a potential targeted therapy for ADH1.

Keywords: Genetic animal models, parathyroid-related disorders, endocrine pathways, hormone replacement/receptor modulators

Introduction

Autosomal dominant hypocalcemia (ADH) is a genetically heterogeneous disorder of extracellular calcium (Ca^{2+}_e) homeostasis consisting of two reported variants. ADH type-1 (ADH1; OMIM #601198) is caused by germline gain-of-function mutations of the G-protein-coupled calcium-sensing receptor (CaSR)^(1,2), and ADH type-2 (ADH2; OMIM #615361) is caused by germline gain-of-function mutations of G-protein subunit α -11 ($\text{G}\alpha_{11}$)⁽³⁻⁶⁾. The CaSR and $\text{G}\alpha_{11}$ proteins signal via multiple pathways including intracellular calcium (Ca^{2+}_i) mobilisation and the ERK arm of the MAPK cascade to regulate PTH secretion and urinary calcium excretion^(7,8). ADH1 is the most common disease variant, with an estimated prevalence of 3.9 cases per 100,000⁽⁹⁾, and is characterized by hypocalcemia, increased circulating phosphate concentrations, inappropriately low or normal PTH concentrations, and a relative hypercalciuria with urinary calcium-to-creatinine ratios that are within or above the reference range^(1,3,10,11). ADH1 has a substantial burden of illness and causes hypocalcemic symptoms such as paraesthesia, muscle spasms and seizures in around 50% of patients⁽¹⁰⁾. Ectopic calcifications are also common in ADH1 and >35% of patients develop basal ganglia calcifications, whilst >10% of patients have nephrocalcinosis⁽¹⁰⁾. Furthermore, patients with severe forms of ADH1 can develop a Bartter-like syndrome characterized by hypokalemic alkalosis, renal salt wasting and hyperreninemic hyperaldosteronism^(12,13).

ADH1 has a high unmet clinical need as conventional therapies such as vitamin D analogs (e.g. alfacalcidol and calcitriol) and calcium supplements predispose ADH1 patients to the development of marked hypercalciuria, nephrocalcinosis, nephrolithiasis and renal

failure^(1,10). Recombinant PTH injections have occasionally been used to treat symptomatic forms of ADH1⁽¹⁴⁾. However, use of this treatment is expensive and limited, as it is administered by *s.c.* bolus injections or continuous pump infusion, and may not prevent ADH1 patients from developing hypercalciuric renal complications⁽¹⁴⁾. Thus, better treatments are required, and antagonists of the CaSR, which are referred to as calcilytics^(15,16), have the potential to act as a targeted therapy for ADH1. To date, all calcilytics are negative allosteric modulators (NAMs) of the CaSR and comprise two main classes of orally active compounds: the amino-alcohols and the quinazolinones. Calcilytics were originally investigated as therapies for osteoporosis, as these compounds transiently stimulated PTH secretion, which had the potential to induce bone anabolic effects⁽¹⁷⁾. However, clinical trials demonstrated that calcilytics have a lack of efficacy for post-menopausal osteoporosis^(18,19), but can lead to sustained elevations in serum calcium concentrations in healthy subjects^(20,21), thereby highlighting the potential of CaSR NAMs to treat hypocalcemic disorders such as ADH. In support of this, calcilytics such as NPS 2143, NPSP795, JTT-305/MK-5442, and AXT914 have been shown to normalize the increased signaling responses associated with ADH1-causing mutant CaSRs *in vitro*⁽²²⁻²⁵⁾, and the calcilytics NPS 2143 and JTT-305/MK-5442 have also been shown to increase plasma calcium and PTH concentrations in ADH1 mouse models *in vivo*^(24,26). However, the effectiveness of calcilytics as treatments for ADH1 patients remains unclear. For example, a phase IIb study involving five ADH1 patients showed that *i.v.* administration of NPSP795 (an amino-alcohol calcilytic compound), at doses ranging from 5-30mg, increased PTH but did not significantly alter ionized blood calcium concentrations⁽²³⁾. We have further evaluated the efficacy of NPSP795 treatment for ADH1 by undertaking *in*

vitro and *in vivo* studies involving *Nuf* mice, which have hypocalcemia (Table 1) in association with a germline gain-of-function CaSR mutation, Leu723Gln. Our findings demonstrate that NPSP795 increases PTH in a dose-dependent manner, and that a higher dose (25 mg/kg) than that used in the reported phase IIb study⁽²³⁾, significantly increases plasma calcium concentrations.

Materials and Methods

Compounds

NPSP795, which is also known as SHP635, was provided by NPS/Shire Pharmaceuticals and dissolved in a 20% aqueous solution of 2-hydroxypropyl- β -cyclodextrin (Sigma) prior to use in *in vitro* and *in vivo* studies.

Animals

All study mice were litter-mates aged between 22-31 weeks. Mice were kept in accordance with Home Office welfare guidance in an environment controlled for light (12 hours light and dark cycle), temperature ($21 \pm 2^\circ\text{C}$) and humidity ($55 \pm 10\%$) at the Medical Research Council (MRC) Harwell Centre⁽²⁷⁾. Mice had free access to water (25 ppm chlorine) and were fed *ad libitum* on a commercial diet (RM3, Special Diet Services) that contained 1.24% calcium, 0.83% phosphorus and 2948 IU/kg of vitamin D. *Nuf* mice (MGI ID: MGI:3054788) were maintained on the inbred 102/H background (strain ID: C3;102-CasrNuf/H; MGI:5291924), which is a substrain bred at the Mary Lyon Centre (Harwell, UK)^(26,28). Animal studies were approved by the MRC Harwell Institute Ethical Review Committee, and were licensed under the Animal (Scientific Procedures) Act 1986, issued by the UK Government Home Office Department (PPL30/2752).

Generation of cells stably expressing the CaSR

HEK293 cells stably expressing the WT and mutant CaSR (TRex-CaSR-WT and TRex-CaSR-Gln723, respectively) were generated using the TRex-HEK293 Flp-In cell-line system

(Invitrogen)^(29,30). WT CaSR was sub-cloned in-frame from a pcDNA3.1+ construct⁽¹⁾ into a pcDNA5/FRT/TO construct (Invitrogen) using the *HindIII* and *ApaI* restriction sites. The mutant CaSR construct was generated by site-directed mutagenesis using the Quikchange Lightning kit (Agilent)⁽³⁾. Mutagenesis and cloning were confirmed using gene-specific primers (SigmaAldrich) and DNA sequence analysis, as reported⁽³⁾. TRex-HEK293 cells were maintained in DMEM Glutamax media (Gibco) supplemented with 10% fetal bovine serum (Gibco), 2mM glutamine (Gibco), 15µg/ml blasticidin (Invitrogen) and 100µg/ml zeocin (Invitrogen). Cells were transfected with 1µg of either WT or mutant CaSR alongside the pOG44 Flp-recombinase expression vector (Invitrogen) using Lipofectamine 2000 (Invitrogen)⁽²⁹⁾. Cells expressing the constructs were selected using 100µg/ml hygromycin B (Invitrogen). Colonies of hygromycin-resistant cells were picked, expanded and expression of CaSR protein was tested in each clonal cell population by Western blot analysis using an anti-CaSR antibody (Abcam), as described⁽³⁾. Calnexin expression was used as a loading control and detected using an anti-calnexin antibody (Millipore). Blots were visualized using an Immuno-Star WesternC kit (BioRad) on a BioRad Chemidoc XRS+ system⁽⁶⁾. Twenty-four hours prior to performance of *in vitro* assays, expression of the CaSR protein was induced using 1µg/ml tetracycline (Invitrogen).

Intracellular calcium measurements

The Ca²⁺_i responses of TRex-CaSR-WT and mutant TRex-CaSR-Gln723 cells were assessed by a flow cytometry-based assay, as reported^(2,3). Briefly, 48 hours post-transfection, the cells were harvested, washed in calcium- and magnesium-free HBSS (Invitrogen) and loaded with

1µg/ml indo-1-acetoxymethylester (Indo-1AM) (Molecular Probes) for 1 hour at 37°C^(2,3). After the removal of free dye, the cells were resuspended in calcium- and magnesium-free HBSS and maintained at 37°C. TRex-CaSR-WT and mutant TRex-CaSR-Gln723 cells were incubated with either a 20% aqueous solution of 2-hydroxypropyl-β-cyclodextrin (vehicle), or NPSP795 at concentrations of 20 nM and 40 nM for 1 hour, as described⁽³¹⁾. Cells in suspension were stimulated by sequentially adding calcium to increase the Ca²⁺_e concentration in a stepwise manner from 0 to 15 mM, and then analysed on a MoFlo modular flow cytometer (Beckman Coulter) by measurement of Ca²⁺_i-bound Indo-1AM (at 410nm), and free Indo-1AM (at 485nm), using a JDSU Xcyte UV laser (Coherent Radiation), on each cell at each Ca²⁺_e concentration, as described^(2,3). Cytomation Summit software was used to determine the peak mean fluorescence ratio of the transient response after each individual stimulus and expressed as a normalized response^(2,3). Concentration-response curves were generated using a 4-parameter non-linear regression curve-fit model (GraphPad Prism) to calculate the half-maximal (EC₅₀) values^(2,3).

Phosphorylated and total ERK measurements

TRex-CaSR-WT and mutant TRex-CaSR-Gln723 cells were seeded in poly-L-lysine treated 48-well plates and incubated for 24 hours. The following day, media was changed to serum-free tetracycline selection media and incubated for a further 12 hours prior to treatment of cells with 0-10mM CaCl₂. Cells were lysed in Surefire lysis buffer, and AlphaScreen Surefire ERK assays measuring phosphorylated and total proteins performed, as described^(6,31). For studies with NPSP795, cells were incubated with either a 20% aqueous solution of 2-hydroxypropyl-β-

cyclodextrin (vehicle), or NPSP795 for 4 hours prior to calcium treatment. The fluorescence signal in both assays was measured using the PheraStar FS microplate reader (BMG Labtech)^(6,31). Fold-change phosphorylated ERK (pERK) responses were expressed as a ratio of pERK to total ERK responses.

***In vivo* administration of NPSP795 to *Nuf* mice**

Mice were randomly allocated to receive NPSP795 or vehicle as a single bolus by *s.c.* injection. None of the mice had undergone any experimental procedures prior to dosing. Study investigators were blinded during animal handling and also when undertaking endpoint measurements. The primary experimental outcome was a change in plasma calcium at 1-hour post-dose in heterozygous (*Casr^{+ / Nuf}*) mice. Blood samples were collected from the lateral tail vein following application of topical local anesthesia for measurement of plasma PTH, or collected from the retro-orbital vein under isoflurane terminal anesthesia for measurement of other plasma biochemical parameters^(26,27).

Plasma biochemical analyses

Plasma was separated by centrifugation at 5000 g for 10 min at 8°C, and analysed for calcium, albumin, phosphate, urea and creatinine on a Beckman Coulter AU680 analyzer, as described⁽²⁶⁾. Plasma calcium was adjusted for variations in albumin concentrations using the formula: (plasma calcium (mmol/l) – [(plasma albumin (g/l) – 30) x 0.02], as reported⁽²⁷⁾. Plasma PTH concentrations were determined using an ELISA for mouse intact PTH (Immutopics)⁽²⁶⁾. Fold-change PTH responses are expressed as a ratio of plasma PTH

concentrations of NPSP795-treated mice to the mean plasma PTH concentrations of respective vehicle-treated mice.

Statistical Analyses

All *in vitro* studies were performed in four biological replicates. For the *in vitro* measurement of Ca^{2+}_i responses, statistical comparisons were undertaken using the *F*-test^(2,3). Fold-change pERK responses were analyzed by two-way ANOVA with Tukey's multiple-comparisons test. Mouse sample size calculations were undertaken using G*Power statistical software. The unit of analysis was a single mouse. A sample size of n=5 mice allocated to the treatment and control groups provided >80% power to detect a >15% increase in plasma calcium concentrations. Biochemical parameters were analysed by one-way ANOVA with Sidak's multiple-comparisons test. All analyses were undertaken using GraphPad Prism (GraphPad), and a value of $p < 0.05$ was considered significant. All data is shown as mean \pm SEM.

Results

Effect of NPSP795 on the signaling responses of cells expressing the gain-of-function mutant Gln723 CaSR

To investigate the effect of NPSP795 on CaSR signal transduction we established cells stably expressing WT CaSR or the *Nuf* mutant Gln723 CaSR, using the TRex Flp-in system^(29,30). Following clonal cell selection, tetracycline addition to the culture media caused a robust overexpression of the CaSR protein in both WT and mutant Gln723 cells (Fig. 1A). We assessed whether NPSP795 could rectify alterations in Ca²⁺_e-mediated Ca²⁺_i responses in the mutant TRex-CaSR-Gln723 cells. As reported previously^(26,28), cells expressing the mutant Gln723 CaSR showed a leftward shift in the Ca²⁺_e-mediated Ca²⁺_i concentration-response curve and a significantly reduced EC₅₀ value (2.41 ± 0.05 mM) when compared with the WT (Leu723) CaSR (EC₅₀ = 2.89 ± 0.07 mM, $p < 0.0001$) (Fig. 1B), consistent with a CaSR gain-of-function. A dose titration of NPSP795 in mutant Gln723 CaSR-expressing cells showed that 20 nM of NPSP795 normalized Ca²⁺_e-mediated Ca²⁺_i responses (EC₅₀ = 2.85 ± 0.13 mM), whereas 40 nM of NPSP795 led to a rightward shift of the mutant receptor concentration-response curve and significantly increased the EC₅₀ value (3.42 ± 0.06 mM, $p < 0.0001$), compared to WT cells (Fig. 1B).

We also investigated the effect of NPSP795 on pERK responses in mutant Gln723 CaSR-expressing cells following exposure to increasing Ca²⁺_e concentrations. The maximal fold-changes in pERK responses of the untreated Gln723 CaSR mutant were shown to be significantly increased compared to WT cells (Gln723 = 24.9 ± 2.3 versus 20.7 ± 4.0 for WT,

$p < 0.05$) (Fig. 1C). Treatment of mutant Gln723 CaSR-expressing cells with 20 nM NPSP795 decreased the maximal pERK fold-change response to 10.4 ± 1.7 , which was not significantly different from WT (Fig. 1C). Thus, a 20 nM dose of NPSP795 normalized the gain-of-function associated with the Leu723Gln CaSR mutation. In contrast, the addition of 40 nM NPSP795 significantly reduced the mutant Gln723 CaSR pERK fold-change response to 6.9 ± 1.0 ($p < 0.001$) compared to WT (Fig. 1C).

Dose-dependent effects of NPSP795 on plasma PTH in *Nuf* mice

As NPSP795 rectified the altered signaling responses associated with the *Nuf* mouse CaSR mutation (Leu723Gln) *in vitro*, we pursued studies to determine the effects of this calcilytic in *Nuf* mice, which have hypocalcemia and reduced plasma PTH concentrations (Table 1). A dose-ranging study was undertaken with NPSP795 to establish the doses required to maximally increase PTH concentrations. NPSP795 was administered at 0, 1, 3, 10 and 30 mg/kg doses by *s.c.* bolus injection to WT and *Casr*^{+/*Nuf*} mice, and at 0, 3, 10 and 30 mg/kg doses to homozygous (*Casr*^{*Nuf/Nuf*}) mice. A plasma sample was obtained at 30 min for PTH measurement. This time-point was selected as plasma PTH concentrations have been reported to be maximally increased at 15-30min following calcilytic administration in rats⁽³²⁾. NPSP795 administration to WT mice led to dose-dependent increases in PTH concentrations, with 10 and 30 mg/kg doses causing maximal elevations of PTH (Fig. 2A). NPSP795 administration also caused dose-dependent PTH elevations in *Casr*^{+/*Nuf*} and *Casr*^{*Nuf/Nuf*} mice, although higher calcilytic doses were required to increase PTH in mutant mice (Fig. 2B-C). Thus, *Casr*^{+/*Nuf*} and *Casr*^{*Nuf/Nuf*} mice required a minimum of 10 mg/kg and 30 mg/kg NPSP795, respectively, to

Accepted Article

significantly increase plasma PTH, compared with a minimum of 3 mg/kg for WT mice (Fig. 2A-C). *Casr^{+Nuf}* and *Casr^{Nuf/Nuf}* mice treated with the highest (30 mg/kg) NPSP795 dose showed significantly reduced plasma PTH concentrations of 371±30 ng/L and 114±18 ng/L, respectively (p <0.0001), compared to a PTH concentration of 931±26 ng/L for WT mice treated with the same dose. However, an analysis of fold-change PTH responses at the 30 mg/kg dose showed that mutant mice have similar or increased PTH responses compared to WT mice (Fig. 2D). Thus, WT and *Casr^{Nuf/Nuf}* mice all showed ≥10-fold increases in plasma PTH compared to respective vehicle-treated mice, whereas *Casr^{+Nuf}* mice showed significantly higher (>15-fold) PTH responses (Fig. 2D).

Time-dependent effects of NPSP795 on plasma PTH, calcium, phosphate, urea and creatinine in *Nuf* mice

To determine whether NPSP795 can rectify the hypocalcemia of *Nuf* mice (Table 1), a sub-maximal dose (25 mg/kg) was administered by *s.c.* bolus injection, and plasma concentrations of adjusted-calcium, phosphate, PTH, urea, and creatinine measured at 0, 0.5, 1, 3 and 6 hours post-dose in WT and *Casr^{+Nuf}* mice, and at 0, 0.5 and 3 hours in *Casr^{Nuf/Nuf}* mice (Fig. 3). Administration of 25 mg/kg NPSP795 led to a maximal rise in plasma PTH concentrations at 30 min post-dose, which returned to baseline values by 3 hours post-dose in WT and *Nuf* mice (Fig. 3A-C). The rise in PTH was associated with significant elevations of plasma calcium at between 1-3 hours post-dose in WT, *Casr^{+Nuf}* and *Casr^{Nuf/Nuf}* mice when compared to respective vehicle-treated mice (Fig. 3D-F). Thus, NPSP795 significantly increased plasma calcium in *Casr^{+Nuf}* mice from 1.87±0.03 mmol/L to 2.16±0.06 mmol/L, and in *Casr^{Nuf/Nuf}* mice from

1.70±0.03 mmol/L to 1.89±0.05 mmol/L (Fig. 3E-F). These increases in plasma calcium of between 0.20-0.30 mmol/L post-dose were similar to that observed for WT mice treated with NPSP795 (Fig. 3D). Administration of this calcilytic also led to significant increases in plasma phosphate in WT and *Casr^{+/Nuf}* mice (Fig. 3G-I). Single dose administration of NPSP795 was well tolerated by the study mice. However, an increase in plasma urea concentrations was observed (Fig. 3J-L), which was associated with normal plasma creatinine concentrations in WT, *Casr^{+/Nuf}* and *Casr^{Nuf/Nuf}* mice treated with NPSP795 (Fig. 3M-O). The causes of an increased plasma urea with normal plasma creatinine include dehydration, heart failure, gastrointestinal bleed, high protein diet and catabolic states due to trauma, starvation and use of glucocorticoid drugs⁽³³⁾. Amongst these the most likely cause was dehydration. Moreover, the rise in plasma urea was transient and had normalized at 6 hours post-dose (Fig. 3J-L).

Discussion

These findings demonstrate that the amino-alcohol calcilytic, NPSP795, rectifies the gain-of-function associated with the *Nuf* mouse germline CaSR mutation, Leu723Gln⁽²⁸⁾, and increases plasma PTH and calcium concentrations in this ADH1 mouse model. We selected 20 nM and 40 nM NPSP795 concentrations for the cellular signaling studies as NPSP795 has a similar potency ($IC_{50} = 73$ nM) to that of the NPS 2143 calcilytic compound ($IC_{50} = 43$ nM)⁽¹⁶⁾, and our previous studies involving NPS 2143 have demonstrated these concentrations to significantly increase the Ca^{2+}_i EC_{50} value of cells expressing the *Nuf* mutant CaSR⁽²⁶⁾. NPSP795 was shown to normalize increases in Ca^{2+}_i and pERK signaling responses of cells stably expressing the *Nuf* mutant CaSR, which is in keeping with the reported effects of NPSP795 on ADH1-causing germline gain-of-function CaSR mutations⁽²³⁾.

Our *in vivo* studies showed that single bolus administration of NPSP795 significantly increases plasma PTH concentrations in a dose-dependent manner in *Nuf* mice. However, substantially higher doses of NPSP795 were required to increase PTH secretion in *Casr^{+/Nuf}* and *Casr^{Nuf/Nuf}* mice compared to that required for WT mice (Fig. 2A-C). This was particularly evident for *Casr^{Nuf/Nuf}* mice, which required 30 mg/kg NPSP795 to increase plasma PTH compared to 3 mg/kg of NPSP795 for WT mice. These findings suggest that parathyroid glands harboring the Gln723 mutant CaSR may have reduced sensitivity to NPSP795 compared to the parathyroid glands of WT mice. However, *Casr^{+/Nuf}* and *Casr^{Nuf/Nuf}* mice given the highest (30 mg/kg) NPSP795 dose had similar or increased fold-change elevations in PTH responses compared to WT mice (Fig. 2D). These results are consistent with the biochemical features of ADH1 being

Accepted Article

rectifiable through normalisation of the parathyroid set-point for PTH release. Moreover, these findings differentiate ADH1 from hypoparathyroidism, which is generally associated with irreversible destruction of the parathyroid glands⁽³⁴⁾. Bolus dose administration of NPSP795 also significantly increased plasma calcium concentrations in *Casr^{+/Nuf}* and *Casr^{Nuf/Nuf}* mice, and the 0.2-0.3 mmol/L increase in plasma calcium was similar to that observed in WT mice treated with NPSP795 (Fig. 3). This finding contrasts with a reported clinical trial involving ADH1 patients, which observed no alterations in ionized blood calcium concentrations of ADH1 patients given 5-30mg of NPSP795 by *i.v.* administration⁽²³⁾. However, our study used a markedly higher (25mg/kg) dose of this calcilytic, and the difference in dosing between the patient and mouse study likely explains the differences observed in circulating calcium responses. The plasma calcium concentrations of *Casr^{+/Nuf}* mice treated with 25 mg/kg of NPSP795 remained significantly lower than that of untreated WT mice (2.16±0.06 mmol/L vs. 2.50±0.04 mmol/L, p<0.01). However, we postulate that repetitive dosing with 25 mg/kg of NPSP795 will lead to normocalcemia in *Casr^{+/Nuf}* mice, as this dose led to substantial (>15-fold) elevations of plasma PTH (Fig. 3B). Consistent with this, a study reporting treatment of ADH1 mice with the JTT-305/MK-5442 calcilytic demonstrated that administration of a single dose (20 µg/g body weight) caused marked increases in serum PTH, but did not normalise serum calcium, whereas longer term administration of this dose induced normocalcemia in ADH1 mice⁽²⁴⁾.

NPSP795 also increased plasma phosphate concentrations in WT and *Casr^{+/Nuf}* mice, and such effects have previously been observed following administration of the NPS 2143 calcilytic

compound to *Nuf* mice and an ADH2 mouse model, which harbors a gain-of-function $G\alpha_{11}$ mutation, Ile62Val^(26,35). The cause of the increase in phosphate is unclear, as calcilytic treatment would be expected to lower plasma phosphate by inducing PTH-mediated renal phosphate excretion⁽⁸⁾. In keeping with this, ADH1 mice harboring a CaSR mutation, Cys129Ser, showed a decrease in serum phosphate concentrations following treatment with the JTT-305/MK-5442 calcilytic compound⁽²⁴⁾. The hyperphosphatemia observed in the current study may potentially have arisen due to dehydration and decreased renal function caused by the acute rise in plasma calcium following NPSP795 treatment, which may activate the kidney CaSR, thereby leading to polyuria⁽³⁶⁾. In support of this WT and *Nuf* mice had elevations of plasma urea, which accompanied the rise in plasma calcium following NPSP795 treatment (Fig. 3). Moreover, the physiological stress associated with drug administration and blood sampling may have reduced water intake in the mice, thus exacerbating the dehydration and consequent increase in plasma urea. However, the increase in plasma urea concentrations appeared to be transient and had normalized in WT and *Casr*^{+/*Nuf*} mice by 6 hours post-dose (Fig. 3).

A limitation of this study is that despite *Casr*^{*Nuf/Nuf*} mice being viable⁽²⁸⁾, fewer homozygotes were born than expected. Thus, the range of NPSP795 doses and study time-points, which could be evaluated in *Casr*^{*Nuf/Nuf*} mice were limited. However, the reduced numbers of *Casr*^{*Nuf/Nuf*} mice did not affect the main objective of this study, which was to evaluate NPSP795 in *Casr*^{+/*Nuf*} mice, as this mouse genotype is a model for ADH1 patients harboring germline heterozygous gain-of-function CaSR mutations. Furthermore, our study only evaluated the

Accepted Article

effect of NPSP795 on the *in vitro* and *in vivo* consequences of a single gain-of-function CaSR mutation. However, it is likely that this calcilytic will be of benefit for a range of ADH1-causing CaSR mutations. Consistent with this, NPSP795 has been previously shown to improve the gain-of-function caused by mutations located in the extracellular (Glu228Ala, Glu228Lys, and Gln245Arg) and transmembrane (Ala840Val) domains of the CaSR⁽²³⁾.

In conclusion, single dose administration of NPSP795 has been shown to cause dose-dependent increases in PTH and to ameliorate the hypocalcemia in an ADH1 mouse model. Thus, the NPSP795 calcilytic represents a potential targeted therapy for ADH1. Longer-term dosing studies are required to investigate whether NPSP795 can rectify the hypocalcemia caused by ADH1.

Acknowledgements

This work was supported by funding from NPS/Shire Pharmaceuticals, and in part by funding from a Wellcome Trust Investigator Award (grant number 106995/Z/15/Z) (to RVT); and Horizon 2020 Programme of the European Union (Project ID: 675228) (to FMH and RVT).

References

1. Pearce SH, Williamson C, Kifor O, Bai M, Coulthard MG, Davies M, et al. A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. *N Engl J Med*. 1996;335(15):1115-22.
2. Hannan FM, Nesbit MA, Zhang C, Cranston T, Curley AJ, Harding B, et al. Identification of 70 calcium-sensing receptor mutations in hyper- and hypo-calcaemic patients: evidence for clustering of extracellular domain mutations at calcium-binding sites. *Hum Mol Genet*. 2012;21(12):2768-78.
3. Nesbit MA, Hannan FM, Howles SA, Babinsky VN, Head RA, Cranston T, et al. Mutations affecting G-protein subunit alpha11 in hypercalcemia and hypocalcemia. *N Engl J Med*. 2013;368(26):2476-86.
4. Mannstadt M, Harris M, Bravenboer B, Chitturi S, Dreijerink KM, Lambright DG, et al. Germline mutations affecting Galpha11 in hypoparathyroidism. *N Engl J Med*. 2013;368(26):2532-4.
5. Piret SE, Gorvin CM, Pagnamenta AT, Howles SA, Cranston T, Rust N, et al. Identification of a G-Protein Subunit-alpha11 Gain-of-Function Mutation, Val340Met, in a Family with Autosomal Dominant Hypocalcemia Type 2 (ADH2). *J Bone Miner Res*. 2016;31:1207-14.
6. Gorvin CM, Babinsky VN, Malinauskas T, Nissen PH, Schou AJ, Hanyaloglu AC, et al. A calcium-sensing receptor mutation causing hypocalcemia disrupts a transmembrane salt bridge to activate β -arrestin biased signaling. *Sci Signal*. 2018; 11(518):eaan3714.
7. Conigrave AD, Ward DT. Calcium-sensing receptor (CaSR): pharmacological properties and signaling pathways. *Best Pract Res Clin Endocrinol Metab*. 2013;27(3):315-31.
8. Hannan FM, Kallay E, Chang W, Brandi ML, Thakker RV. The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases. *Nat Rev Endocrinol*. 2018;15(1):33-51.
9. Dershem R, Gorvin CM, Metpally RPR, Krishnamurthy S, Smelser DT, Hannan FM, et al. Familial Hypocalciuric Hypercalcemia Type 1 and Autosomal-Dominant Hypocalcemia Type 1: Prevalence in a Large Healthcare Population. *Am J Hum Genet*. 2020; 106(6):734-747.
10. Raue F, Pichl J, Dorr HG, Schnabel D, Heidemann P, Hammersen G, et al. Activating mutations in the calcium-sensing receptor: genetic and clinical spectrum in 25 patients with autosomal dominant hypocalcaemia - a German survey. *Clin Endocrinol (Oxf)*. Dec 2011;75(6):760-5.
11. Yamamoto M, Akatsu T, Nagase T, Ogata E. Comparison of hypocalcemic hypercalciuria between patients with idiopathic hypoparathyroidism and those with gain-of-function mutations in the calcium-sensing receptor: is it possible to differentiate the two disorders? *J Clin Endocrinol Metab*. 2000;85(12):4583-91.
12. Vargas-Poussou R, Huang C, Hulin P, Houillier P, Jeunemaitre X, Paillard M, et al. Functional characterization of a calcium-sensing receptor mutation in severe

- autosomal dominant hypocalcemia with a Bartter-like syndrome. *J Am Soc Nephrol.* 2002;13(9):2259-66.
13. Watanabe S, Fukumoto S, Chang H, Takeuchi Y, Hasegawa Y, Okazaki R, et al. Association between activating mutations of calcium-sensing receptor and Bartter's syndrome. *Lancet.* 2002;360(9334):692-4.
 14. Theman TA, Collins MT, Dempster DW, Zhou H, Reynolds JC, Brahim JS, et al. PTH(1-34) replacement therapy in a child with hypoparathyroidism caused by a sporadic calcium receptor mutation. *J Bone Miner Res.* 2009;24(5):964-73.
 15. Hannan FM, Olesen MK, Thakker RV. Calcimimetic and calcilytic therapies for inherited disorders of the calcium-sensing receptor signalling pathway. *Br J Pharmacol.* 2018;175(21):4083-94.
 16. Nemeth EF, Van Wagenen BC, Balandrin MF. Discovery and Development of Calcimimetic and Calcilytic Compounds. *Prog Med Chem.* 2018;57(1):1-86.
 17. Gowen M, Stroup GB, Dodds RA, James IE, Votta BJ, Smith BR, et al. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. *J Clin Invest.* 2000;105(11):1595-604.
 18. Fitzpatrick LA, Dabrowski CE, Cicconetti G, Gordon DN, Papapoulos S, Bone HG, 3rd, et al. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density. *J Clin Endocrinol Metab.* 2011;96(8):2441-9.
 19. Halse J, Greenspan S, Cosman F, Ellis G, Santora A, Leung A, et al. A phase 2, randomized, placebo-controlled, dose-ranging study of the calcium-sensing receptor antagonist MK-5442 in the treatment of postmenopausal women with osteoporosis. *J Clin Endocrinol Metab.* 2014;99(11):E2207-15.
 20. Caltabiano S, Dollery CT, Hossain M, Kurtinecz MT, Desjardins JP, Favus MJ, et al. Characterization of the effect of chronic administration of a calcium-sensing receptor antagonist, ronacaleret, on renal calcium excretion and serum calcium in postmenopausal women. *Bone.* 2013;56(1):154-62.
 21. John MR, Harfst E, Loeffler J, Belleli R, Mason J, Bruin GJ, et al. AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women. *Bone.* 2014;64:204-10.
 22. Letz S, Rus R, Haag C, Dorr HG, Schnabel D, Mohlig M, et al. Novel activating mutations of the calcium-sensing receptor: the calcilytic NPS-2143 mitigates excessive signal transduction of mutant receptors. *J Clin Endocrinol Metab.* 2010;95(10):E229-33.
 23. Roberts MS, Gafni RI, Brillante B, Guthrie LC, Streit J, Gash D, et al. Treatment of Autosomal Dominant Hypocalcemia Type 1 With the Calcilytic NPS795 (SHP635). *J Bone Miner Res.* 2019;34(9):1609-18.
 24. Dong B, Endo I, Ohnishi Y, Kondo T, Hasegawa T, Amizuka N, et al. Calcilytic Ameliorates Abnormalities of Mutant Calcium-Sensing Receptor (CaSR) Knock-in Mice Mimicking Autosomal Dominant Hypocalcemia (ADH). *J Bone Miner Res.* 2015;30:1980-93.
 25. Letz S, Haag C, Schulze E, Frank-Raue K, Raue F, Hofner B, et al. Amino alcohol-(NPS-2143) and quinazolinone-derived calcilytics (ATF936 and AXT914)

differentially mitigate excessive signalling of calcium-sensing receptor mutants causing Bartter syndrome Type 5 and autosomal dominant hypocalcemia. *PLoS One*. 2014;9(12):e115178.

26. Hannan FM, Walls GV, Babinsky VN, Nesbit MA, Kallay E, Hough TA, et al. The Calcilytic Agent NPS 2143 Rectifies Hypocalcemia in a Mouse Model With an Activating Calcium-Sensing Receptor (CaSR) Mutation: Relevance to Autosomal Dominant Hypocalcemia Type 1 (ADH1). *Endocrinology*. 2015;156(9):3114-21.
27. Babinsky VN, Hannan FM, Ramracheya RD, Zhang Q, Nesbit MA, Hugill A, et al. Mutant Mice With Calcium-Sensing Receptor Activation Have Hyperglycemia That Is Rectified by Calcilytic Therapy. *Endocrinology*. 2017;158(8):2486-502.
28. Hough TA, Bogani D, Cheeseman MT, Favor J, Nesbit MA, Thakker RV, et al. Activating calcium-sensing receptor mutation in the mouse is associated with cataracts and ectopic calcification. *Proc Natl Acad Sci U S A*. 2004;101(37):13566-71.
29. Leach K, Wen A, Davey AE, Sexton PM, Conigrave AD, Christopoulos A. Identification of molecular phenotypes and biased signaling induced by naturally occurring mutations of the human calcium-sensing receptor. *Endocrinology*. 2012;153(9):4304-16.
30. Davey AE, Leach K, Valant C, Conigrave AD, Sexton PM, Christopoulos A. Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor. *Endocrinology*. 2012;153(3):1232-41.
31. Babinsky VN, Hannan FM, Gorvin CM, Howles SA, Nesbit MA, Rust N, et al. Allosteric Modulation of the Calcium-sensing Receptor Rectifies Signaling Abnormalities Associated with G-protein alpha-11 Mutations Causing Hypercalcemic and Hypocalcemic Disorders. *J Biol Chem*. 2016;291(20):10876-85.
32. Nemeth EF, Delmar EG, Heaton WL, Miller MA, Lambert LD, Conklin RL, et al. Calcilytic compounds: potent and selective Ca²⁺ receptor antagonists that stimulate secretion of parathyroid hormone. *J Pharmacol Exp Ther*. 2001;299(1):323-31.
33. Higgins C. Urea and creatinine concentration, the urea:creatinine ratio. www.acutecaretesting.org2016.
34. Mannstadt M, Bilezikian JP, Thakker RV, Hannan FM, Clarke BL, Reijnmark L, et al. Hypoparathyroidism. *Nat Rev Dis Primers*. 2017;3:17055.
35. Gorvin CM, Hannan FM, Howles SA, Babinsky VN, Piret SE, Rogers A, et al. *Gα11* mutation in mice causes hypocalcemia rectifiable by calcilytic therapy. *JCI Insight*. 2017;2:e91103.
36. Renkema KY, Velic A, Dijkman HB, Verkaart S, van der Kemp AW, Nowik M, et al. The calcium-sensing receptor promotes urinary acidification to prevent nephrolithiasis. *J Am Soc Nephrol*. 2009;20(8):1705-13.

Figure legends

Fig. 1. Effect of NPSP795 on the signaling responses of cells stably expressing the WT or mutant Gln723 CaSR. (A) Western blot analysis of lysates from TRex-CaSR-WT and mutant TRex-CaSR-Gln723 cells demonstrating that addition of tetracycline (Tet) induces increased CaSR expression. Calnexin was used as a housekeeping protein. (B) Ca^{2+}_i response to changes in Ca^{2+}_e concentrations of TRex-CaSR-WT and mutant TRex-CaSR-Gln723 cells. The Ca^{2+}_i responses to changes in Ca^{2+}_e concentrations are expressed as a percentage of the maximum normalized responses. The Gln723 CaSR mutant led to a leftward shift in the concentration-responses curve (solid red line). The addition of 20nM NPSP795 rectified the leftward shift of the Gln723 CaSR mutant (dashed red line), whereas 40nM NPSP795 caused a rightward shift of the Gln723 CaSR mutant (dotted red line) compared to WT (solid black line). Dotted black lines indicate the EC_{50} values for respective WT and mutant cells. A close-up view of the concentration-response curves at the half-maximal response is also shown. (C) pERK fold-change response to changes in Ca^{2+}_e concentrations of TRex-CaSR-WT and mutant TRex-CaSR-Gln723 cells. The fold-change responses of pERK are expressed as a ratio of the total ERK response. The Gln723 mutant (solid red line) led to significantly increased pERK fold-change responses compared to WT (solid black line). The addition of 20nM NPSP795 normalized the pERK fold-change responses of the Gln723 mutant (dashed red line), whereas 40nM NPSP795 significantly reduced pERK responses (dotted red line) compared to WT. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ compared to WT.

Fig. 2. Dose-dependent effects of NPSP795 on the plasma PTH responses of WT, *Casr*^{+/*Nuf*} and *Casr*^{*Nuf*/*Nuf*} mice. (A-C) Plasma PTH concentrations were measured in (A) WT, (B) *Casr*^{+/*Nuf*}, and (C) *Casr*^{*Nuf*/*Nuf*} mice following administration of NPSP795 at doses ranging from 0 to 30 mg/kg. (D) Fold-change plasma PTH responses following administration of 30mg/kg NPSP795 to WT (+/+), *Casr*^{+/*Nuf*} (+/*Nuf*), and *Casr*^{*Nuf*/*Nuf*} (*Nuf*/*Nuf*) mice. Fold-changes in plasma PTH are expressed as a ratio of the PTH values of NPSP795-treated mice to the mean plasma PTH values of respective vehicle-treated mice. Male and female mice are represented by squares and circles respectively. Mean ± SEM values for the respective groups are indicated by solid bars. *p<0.05, **p<0.01, ***p<0.001.


Fig. 3. Time-dependent effects of NPSP795 on plasma PTH, calcium, phosphate, urea, and creatinine concentrations in WT, *Casr*^{+/*Nuf*} and *Casr*^{*Nuf*/*Nuf*} mice. Plasma concentrations of (A-C) PTH, (D-F) adjusted calcium, (G-I) phosphate, (J-L) urea, and (M-O) creatinine are shown in WT and *Casr*^{+/*Nuf*} mice at 0, 0.5, 1, 3 and 6 hours, and at 0, 0.5 and 3 hours in *Casr*^{*Nuf*/*Nuf*} mice. Male and female mice are represented by squares and circles respectively. Mean ± SEM values for the respective groups are indicated by solid bars. *p<0.05, **p<0.01, ***p<0.001, NS, not significant

Table 1. Age and plasma biochemistry of WT, *Casr*^{+/*Nuf*} and *Casr*^{*Nuf/Nuf*} mice^a.


	Male			Female		
	+/+	+/ <i>Nuf</i>	<i>Nuf/Nuf</i>	+/+	+/ <i>Nuf</i>	<i>Nuf/Nuf</i>
Number of mice	n=6	n=5	n=6	n=5	n=6	n=5
Age (weeks)	30.1±0.9	29.4±0.7	28.3±1.4	28.7±1.1	29.5±0.5	31.0±1.6
Tot-Ca (mmol/l)	2.40±0.05	1.82±0.03***	1.71±0.03***	2.53±0.02	1.89±0.05***	1.73±0.05***
Albumin (g/l)	28.4±0.7	29.1±0.5	28.5±0.2	30.6±1.2	29.8±1.3	29.9±0.7
Adj-Ca (mmol/l)	2.43±0.04	1.83±0.03***	1.74±0.03***	2.52±0.03	1.89±0.03***	1.73±0.05***
Phosphate (mmol/l)	1.39±0.09	2.09±0.21	2.26±0.3*	1.10±0.15	1.79±0.2	2.19±0.19*
ALP (U/l)	62.7±10.8	76.6±4.5	60.3±9.1	126±13	77.8±7.4*	99.5±11
PTH (ng/l)	89.7±16	12.9±3.0***	3.0±1.5***	51.7±16	16.8±4.5*	7.6±3.0*
Urea (mmol/l)	9.6±0.8	9.6±0.7	10.8±0.7	9.0±0.7	9.8±0.9	9.9±1.3
Creatinine (μmol/l)	11.1±0.9	12.0±0.8	11.6±0.6	15.9±1.4	16.2±1.2	15.7±1.3

^aAge and biochemical parameters of untreated male and female WT (+/+), *Casr*^{+/*Nuf*} (+/*Nuf*), and *Casr*^{*Nuf/Nuf*} (*Nuf/Nuf*) mice are shown. Tot-Ca, total calcium; Adj-Ca, albumin-adjusted calcium; ALP, alkaline phosphatase activity. *p < 0.05, ***p < 0.0001 compared to WT (+/+) mice. All data is shown as mean ± SEM.

A








B



- Leu723 (WT) $EC_{50}=2.89\text{mM}$ (95%CI 2.75-3.03)
- Gln723 (m) $EC_{50}= 2.41\text{mM}$ (95% CI 2.31-2.49)^{***}
- Gln723 (m) + 20nM $EC_{50}= 2.85\text{mM}$ (95% CI 2.45-2.97)
- ▲ Gln723 (m) + 40nM $EC_{50}= 3.42\text{mM}$ (95% CI 3.30-3.53)^{***}

C





This article is protected by copyright. All rights reserved.

